XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

VALLEY COTTAGE, N.Y., Feb. 7 XTLBiopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that RonBentsur, the Company's Chief Executive Officer, is scheduled to present at the10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present anoverview of the Company including a discussion of Bicifadine, the Company'slate-stage clinical compound for the treatment of diabetic neuropathic pain.Mr. Bentsur's presentation will take place on Wednesday, February 13, 2008 at1:15 pm EST at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available at:http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=XTL&item_id=1752502.An archived version of the webcast will be available following the conclusionof the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") isengaged in the development of therapeutics for the treatment of neuropathicpain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrinereuptake inhibitor, for the treatment of diabetic neuropathic pain, which iscurrently in a Phase 2b study. XTL is also developing novel pre-clinical HCVsmall molecule inhibitors. XTL also has an active in-licensing and acquisitionprogram designed to identify and acquire additional drug candidates. XTL ispublicly traded on the NASDAQ and Tel-Aviv Stock Exchanges(Nasdaq: XTLB; TASE: XTL).

SOURCE XTL Biopharmaceuticals Ltd.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...